Metrics as of 10/14/2026, 05:48 AM (Berlin time), refresh in progress.
OnKure Therapeutics Stock
OnKure Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Nicholas A. Saccomano
- Employees
- 45
- Market cap
- $95 M
- IPO
- 08/04/2021
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current…
OnKure Therapeutics stock: price history
1D
-2.9%
1W
-4.5%
1M
-24.2%
6M
-49.0%
YTD
-19.0%
1Y
-18.4%
2Y
-87.2%
5Y
-96.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~30% weaker price swings than usual
Ask the agents about OnKure Therapeutics
Analyst assessment of OnKure Therapeutics
PRICE TARGET LOW
US$14.00
CONSENSUS
US$14.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 14/08/2026
OnKure Therapeutics stock metrics
P/E
-0.67
P/B
0.68
EV/EBITDA
1.22
RETURN ON EQUITY
-8.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.2%
FLOAT SHARES
29,232,983
AVG. DAILY VOLUME (30D)
323,663
Insider transactions (SEC)
Saccomano Nicholas A
Leverone Jason A.
Saccomano Nicholas A
Leverone Jason A.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about OnKure Therapeutics stock
What does OnKure Therapeutics do?
OnKure Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Nicholas A. Saccomano, the company employs around 45 people.
The IPO was on 08/04/2021; the stock trades on NASDAQ under the ticker OKUR.
What do analysts say about OnKure Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$14.00, ranging from US$14.00 to US$14.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does OnKure Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -30% stronger than usual.
Does OnKure Therapeutics pay a dividend?
No, OnKure Therapeutics currently does not pay a dividend.
Which stocks are comparable to OnKure Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get OnKure Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess OnKure Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.